Which has stronger earnings & valuation, ABBV or AMGN?

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 8.52 $4.23B $5.81 50.73 Amgen $38.90B 6.49 $7.71B $17.24 27.09

Is ABBV or AMGN more profitable?

Amgen has a net margin of 24.14% compared to AbbVie's net margin of 15.67%. Amgen's return on equity of 114.99% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 15.67% -450.55% 16.50% Amgen 24.14% 114.99% 13.47%

Does the media prefer ABBV or AMGN?

In the previous week, Amgen had 6 more articles in the media than AbbVie. MarketBeat recorded 53 mentions for Amgen and 47 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Amgen's score of 0.65 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 36 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 22 Very Positive mention(s) 6 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is ABBV or GILD more profitable?

AbbVie has a net margin of 15.67% compared to Gilead Sciences' net margin of -12.47%. Gilead Sciences' return on equity of -1.85% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 15.67% -450.55% 16.50% Gilead Sciences -12.47% -1.85% -0.61%

Does the media prefer ABBV or GILD?

In the previous week, AbbVie had 7 more articles in the media than Gilead Sciences. MarketBeat recorded 47 mentions for AbbVie and 40 mentions for Gilead Sciences. AbbVie's average media sentiment score of 1.14 beat Gilead Sciences' score of 0.83 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 36 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 24 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation & earnings, ABBV or MRNA?

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 8.52 $4.23B $5.81 50.73 Moderna $1.94B 48.15 -$2.82B -$7.10 N/A

Is ABBV or MRNA more profitable?

AbbVie has a net margin of 15.67% compared to Moderna's net margin of -110.46%. Moderna's return on equity of -25.79% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 15.67% -450.55% 16.50% Moderna -110.46% -25.79% -15.85%

Does the media prefer ABBV or MRNA?

In the previous week, Moderna had 36 more articles in the media than AbbVie. MarketBeat recorded 83 mentions for Moderna and 47 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Moderna's score of 0.60 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 36 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 30 Very Positive mention(s) 15 Positive mention(s) 19 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Positive

Is ABBV or ABT more profitable?

AbbVie has a net margin of 15.67% compared to Abbott Laboratories' net margin of 9.75%. Abbott Laboratories' return on equity of 18.04% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 15.67% -450.55% 16.50% Abbott Laboratories 9.75% 18.04% 9.09%

Does the media refer more to ABBV or ABT?

In the previous week, AbbVie had 12 more articles in the media than Abbott Laboratories. MarketBeat recorded 47 mentions for AbbVie and 35 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.16 beat AbbVie's score of 1.14 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 36 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, AZN or ABBV?

AstraZeneca has higher earnings, but lower revenue than AbbVie. AstraZeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca $58.74B 4.87 $10.23B $7.07 26.09 AbbVie $61.16B 8.52 $4.23B $5.81 50.73

Is AZN or ABBV more profitable?

AstraZeneca has a net margin of 17.68% compared to AbbVie's net margin of 15.67%. AstraZeneca's return on equity of 31.85% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.68% 31.85% 13.62% AbbVie 15.67% -450.55% 16.50%

Does the media favor AZN or ABBV?

In the previous week, AbbVie had 33 more articles in the media than AstraZeneca. MarketBeat recorded 47 mentions for AbbVie and 14 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.18 beat AbbVie's score of 1.14 indicating that AstraZeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 36 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

AbbVie (ABBV) Competitors

$295.18 +0.73 (+0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$294.15 -1.03 (-0.35%)

As of 06:09 PM Eastern

Compare

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you buy AbbVie stock or one of its competitors? AbbVie's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and AstraZeneca (AZN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AbbVie compare to Amgen?

AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Amgen has a net margin of 24.14% compared to AbbVie's net margin of 15.67%. Amgen's return on equity of 114.99% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	15.67%	-450.55%	16.50%
Amgen	24.14%	114.99%	13.47%

AbbVie presently has a consensus price target of $297.46, indicating a potential upside of 0.92%. Amgen has a consensus price target of $424.66, indicating a potential downside of 9.08%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83
Amgen	3 Sell rating(s)	18 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.30

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.3%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.2%. AbbVie pays out 119.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 58.5% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Amgen has increased its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.73
Amgen	$38.90B	6.49	$7.71B	$17.24	27.09

In the previous week, Amgen had 6 more articles in the media than AbbVie. MarketBeat recorded 53 mentions for Amgen and 47 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Amgen's score of 0.65 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	36 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	22 Very Positive mention(s)	6 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Amgen beats AbbVie on 10 of the 19 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

AbbVie (NYSE:ABBV) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

AbbVie has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

AbbVie presently has a consensus price target of $297.46, suggesting a potential upside of 0.92%. Gilead Sciences has a consensus price target of $171.07, suggesting a potential upside of 1.86%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.79

AbbVie has a net margin of 15.67% compared to Gilead Sciences' net margin of -12.47%. Gilead Sciences' return on equity of -1.85% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	15.67%	-450.55%	16.50%
Gilead Sciences	-12.47%	-1.85%	-0.61%

Gilead Sciences has lower revenue, but higher earnings than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.73
Gilead Sciences	$30.99B	6.72	$8.51B	-$3.16	N/A

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.3%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.0%. AbbVie pays out 119.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out -103.8% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, AbbVie had 7 more articles in the media than Gilead Sciences. MarketBeat recorded 47 mentions for AbbVie and 40 mentions for Gilead Sciences. AbbVie's average media sentiment score of 1.14 beat Gilead Sciences' score of 0.83 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	36 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	24 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

AbbVie beats Gilead Sciences on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Moderna?

AbbVie (NYSE:ABBV) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.73
Moderna	$1.94B	48.15	-$2.82B	-$7.10	N/A

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AbbVie has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Moderna has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

In the previous week, Moderna had 36 more articles in the media than AbbVie. MarketBeat recorded 83 mentions for Moderna and 47 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Moderna's score of 0.60 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	36 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	30 Very Positive mention(s)	15 Positive mention(s)	19 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Positive

AbbVie has a net margin of 15.67% compared to Moderna's net margin of -110.46%. Moderna's return on equity of -25.79% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	15.67%	-450.55%	16.50%
Moderna	-110.46%	-25.79%	-15.85%

AbbVie presently has a consensus target price of $297.46, indicating a potential upside of 0.92%. Moderna has a consensus target price of $113.75, indicating a potential downside of 50.83%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83
Moderna	4 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

AbbVie beats Moderna on 10 of the 16 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

AbbVie (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

AbbVie has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Abbott Laboratories has lower revenue, but higher earnings than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.73
Abbott Laboratories	$44.33B	4.19	$6.52B	$2.68	40.01

AbbVie has a net margin of 15.67% compared to Abbott Laboratories' net margin of 9.75%. Abbott Laboratories' return on equity of 18.04% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	15.67%	-450.55%	16.50%
Abbott Laboratories	9.75%	18.04%	9.09%

AbbVie currently has a consensus target price of $297.46, indicating a potential upside of 0.92%. Abbott Laboratories has a consensus target price of $118.32, indicating a potential upside of 10.35%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, AbbVie had 12 more articles in the media than Abbott Laboratories. MarketBeat recorded 47 mentions for AbbVie and 35 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.16 beat AbbVie's score of 1.14 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	36 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.3%. Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.4%. AbbVie pays out 119.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories pays out 94.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years and Abbott Laboratories has increased its dividend for 54 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Abbott Laboratories beats AbbVie on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to AstraZeneca?

AstraZeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

AstraZeneca has higher earnings, but lower revenue than AbbVie. AstraZeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	$58.74B	4.87	$10.23B	$7.07	26.09
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.73

AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.3%. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. AbbVie pays out 119.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AstraZeneca has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AbbVie had 33 more articles in the media than AstraZeneca. MarketBeat recorded 47 mentions for AbbVie and 14 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.18 beat AbbVie's score of 1.14 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	36 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AstraZeneca has a net margin of 17.68% compared to AbbVie's net margin of 15.67%. AstraZeneca's return on equity of 31.85% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.68%	31.85%	13.62%
AbbVie	15.67%	-450.55%	16.50%

AstraZeneca currently has a consensus price target of $206.67, indicating a potential upside of 12.04%. AbbVie has a consensus price target of $297.46, indicating a potential upside of 0.92%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

AbbVie beats AstraZeneca on 11 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$521.77B	$4.10B	$7.86B	$23.55B
Dividend Yield	2.35%	3.62%	2.46%	3.74%
P/E Ratio	50.81	24.56	34.60	29.91
Price / Sales	8.53	16.88	8.89	3.42
Price / Cash	19.48	26.89	22.23	15.68
Price / Book	-114.86	4.14	4.40	3.72
Net Income	$4.23B	-$22.78M	$3.51B	$1.08B
7 Day Performance	1.26%	-2.72%	-1.50%	0.61%
1 Month Performance	7.41%	-5.72%	-3.92%	-0.29%
1 Year Performance	27.10%	-0.31%	0.90%	6.82%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	3.7969 of 5 stars	$295.18 +0.2%	$297.46 +0.8%	+26.3%	$521.77B	$61.16B	50.81	57,000	Trending News Insider Trade
AMGN Amgen	4.0735 of 5 stars	$461.01 +0.2%	$419.10 -9.1%	+38.9%	$249.40B	$36.75B	26.76	31,500	Trending News Analyst Forecast
GILD Gilead Sciences	3.4504 of 5 stars	$167.43 -0.1%	$170.15 +1.6%	+36.1%	$207.91B	$29.44B	N/A	17,000	Trending News Analyst Forecast Analyst Revision
MRNA Moderna	1.7085 of 5 stars	$257.49 +6.6%	$107.10 -58.4%	+766.2%	$103.40B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Revision Gap Down
ABT Abbott Laboratories	4.2717 of 5 stars	$111.16 -2.1%	$118.32 +6.4%	-16.8%	$192.54B	$48.23B	41.52	115,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors